Chinese scholars have found anti-cancer targets to control the lifeblood of gliomas in the brain

Researchers from the Virginia Tech-Galiion Research Institute (VTCRI) say a gene involved in human biological rhythms may be a potential therapeutic target for deadly gliomas. The new findings, published recently in Scientific Reports and titled "Casein Kinase 1 Epsilon Regulations Glioblastoma Cell Survival," suggest that a specific gene can clearly keep tumor cells alive, even though the gene is usually associated with biological rhythms.
"The world has spared no effort to find a cure for glioma, but no one has previously found this gene to be one of the targets for the treatment of glioma." The study's author, Zhi Sheng, an associate professor at VTCRI, said his team identified the gene from 20 suspicious genes.
"We have found that inhibiting this gene may inhibit the ability of tumor stem cells to self-renew and differentiate into glioma cells, which are considered to be one of the characteristics of this type of hard-to-treat cancer." "Sheng said." Although more research is needed before a new treatment can be designed, our early basic research is promising. Sheng
that patients with gliomas around the world are in urgent need of new treatments. Most patients survive less than 15 months after diagnosis, 90% of patients who survive more than 2 years will relapse, and patients with relapsed gliomas will often be unable to perform surgery. The disease causes almost half of all brain cancer deaths.
said that even if only a few hundred glioma stem cells survived surgery, radiotherapy and chemotherapy, the cancer would return. But in their experiments on cancer cells and mouse models, the researchers found that when enzymes produced by a member of the casein kinase 1 family were inhibited, the proliferation of glioma stem cells stopped and tumor growth in mice was inhibited.
also found evidence that the enzyme regulates the rate at which glioma stem cells self-renew, rather than controlling differentiation. "Suppressing this gene can effectively kill glioma stem cells." Sheng said. Sheng and his colleagues also evaluated two commercially available drugs that inhibit casein kinase 1 and found that one of them had the potential for further research into becoming a glioma stem cell inhibitor. (Bio Valley)